An unresolved issue in rhabdomyosarcoma treatment: The duration of chemotherapy
暂无分享,去创建一个
[1] A. Ferrari,et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. , 2019, The Lancet. Oncology.
[2] W. Meyer. Maintenance chemotherapy in rhabdomyosarcoma: the new standard of care. , 2019, The Lancet. Oncology.
[3] S. Donaldson,et al. Increased local failure for patients with intermediate‐risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group , 2019, Cancer.
[4] A. Ferrari,et al. Rhabdomyosarcoma , 2019, Nature Reviews Disease Primers.
[5] James R. Anderson,et al. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma , 2018, Cancer.
[6] James R. Anderson,et al. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Stevens,et al. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. , 2018, The Lancet. Oncology.
[8] E. Koscielniak,et al. Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned. , 2018, Cancer treatment reviews.
[9] K. McHugh,et al. Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). , 2017, European journal of cancer.
[10] James R. Anderson,et al. Reduction of cyclophosphamide dose for patients with subset 2 low‐risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group , 2017, Cancer.
[11] James R. Anderson,et al. Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups , 2015, Pediatric blood & cancer.
[12] James R. Anderson,et al. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Merks. Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] M. Stevens,et al. Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] S. Spunt,et al. Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas , 2013, Pediatric blood & cancer.
[16] M. Stevens,et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Carli,et al. Long‐term results in childhood rhabdomyosarcoma: A report from the Italian cooperative study RMS 79 , 2012, Pediatric blood & cancer.
[18] James R. Anderson,et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's O , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] James R. Anderson,et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Schmelzle,et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] H. B. Marsden,et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Ferrari,et al. Paratesticular rhabdomyosarcoma: report from the Italian and German Cooperative Group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] James R. Anderson,et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] James R. Anderson,et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Henze,et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] P. Voûte,et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. , 1998, European journal of cancer.
[27] E. Gehan,et al. The Third Intergroup Rhabdomyosarcoma Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] E. Gehan,et al. The intergroup rhabdomyosarcoma study‐II , 1993, Cancer.
[29] H. Jürgens,et al. Treatment of soft tissue sarcoma in childhood and adolescence: A report of the german cooperative soft tissue sarcoma study , 1992, Cancer.
[30] E. Gehan,et al. The intergroup rhabdomyosarcoma study‐I. A final report , 1988, Cancer.
[31] P. Voûte,et al. Prognostic factors in 281 children with nonmetastatic rhabdomyosarcoma (RMS) at diagnosis. , 1988, Medical and pediatric oncology.